1. Gulati S, Jain S. Ocular pharmacology of tear film, dry eye, and allergic conjunctivitis.
Handb Exp Pharmacol 2017;242:97-118.
2. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia.
Ophthalmology 1998;105:1114-1119.
3. Kuang TM, Tsai SY, Hsu WM, et al. Correctable visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study.
Invest Ophthalmol Vis Sci 2007;48:1032-1037.
4. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life.
Am J Ophthalmol 2007;143:409-415.
5. Versura P, Profazio V, Schiavi C, Campos EC. Hyperosmolar stress upregulates HLA-DR expression in human conjunctival epithelium in dry eye patients and in vitro models.
Invest Ophthalmol Vis Sci 2011;52:5488-5496.
6. Bellotti M, Bast W, Berra A, Bonetto FJ. Effects of osmolarity on human epithelial conjunctival cells using an electrical technique.
Graefes Arch Clin Exp Ophthalmol 2011;249:1875-1882.
7. Julio G, Lluch S, Pujol P, Merindano MD. Effects of tear hyperosmolarity on conjunctival cells in mild to moderate dry eye.
Ophthalmic Physiol Opt 2012;32:317-323.
8. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells.
Invest Ophthalmol Vis Sci 2004;45:4302-4311.
9. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells.
Exp Eye Res 2006;82:588-596.
10. Cavet ME, Harrington KL, Ward KW, Zhang JZ. Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells.
Mol Vis 2010;16:1791-1800.
11. Al-Ayyoubi S, Gali-Muhtasib H. Differential apoptosis by gallotannin in human colon cancer cells with distinct p53 status.
Mol Carcinog 2007;46:176-186.
12. Neuhofer W. Role of NFAT5 in inflammatory disorders associated with osmotic stress.
Curr Genomics 2010;11:584-590.
13. Schwartz L, Guais A, Pooya M, Abolhassani M. Is inflammation a consequence of extracellular hyperosmolarity?
J Inflamm (Lond) 2009;6:21
14. Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: a novel dry eye therapy.
Expert Opin Investig Drugs 2004;13:47-54.
15. Gum SI, Kim YH, Jung JC, et al. Cyclosporine A inhibits TGF-β2-induced myofibroblasts of primary cultured human pterygium fibroblasts.
Biochem Biophys Res Commun 2017;482:1148-1153.
16. Kanellopoulos AJ, Asimellis G. In pursuit of objective dry eye screening clinical techniques.
Eye Vis (Lond) 2016;3:1
17. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the d iagnosis and management of d ry eye d isease.
Am J Ophthalmol 2011;151:792-798.
18. Corrales RM, Villarreal A, Farley W, et al. Strain-related cytokine profiles on the murine ocular surface in response to desiccating stress.
Cornea 2007;26:579-584.
19. Gilbard JP, Carter JB, Sang DN, et al. Morphologic effect of hyperosmolarity on rabbit corneal epithelium.
Ophthalmology 1984;91:1205-1212.
20. Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface.
Eye Contact Lens 2005;31:186-193.
21. Pan Z, Wang Z, Yang H, et al. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells.
Invest Ophthalmol Vis Sci 2011;52:485-493.
22. Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome.
Am J Ophthalmol 2009;147:198-205.
23. Enriquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.
Mol Vis 2010;16:862-873.
24. Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes.
Clin Ophthalmol 2015;9:865-872.
25. Park JH, Moon SH, Kang DH, et al. Diquafosol sodium inhibits apoptosis and inf lammation of corneal epithelial cells via activation of Erk1/2 and RSK: in vitro and in vivo dry eye model.
Invest Ophthalmol Vis Sci 2018;59:5108-5115.
26. Lan W, Petznick A, Heryati S, et al. Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases.
Ocul Surf 2012;10:137-148.
28. Guzman M, Keitelman I, Sabbione F, et al. Desiccating stress-induced disruption of ocular surface immune tolerance drives dry eye disease.
Clin Exp Immunol 2016;184:248-256.
29. Fujihara T, Murakami T, Fujita H, et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.
Invest Ophthalmol Vis Sci 2001;42:96-100.
30. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients.
Cornea 2009;28:1023-1027.